Cladribine tablets added to IFN-β in active relapsing MS
Authors:
- Xavier MontalbanXMXavier Montalban
- Thomas P. LeistTLThomas P. Leist
- Bruce A. CohenBCBruce A. Cohen
- Harold MosesHMHarold Moses
- Jackie CampbellJCJackie Campbell
- Christine HickingCHChristine Hicking
- Fernando DangondFDFernando Dangond
Open Access
- 1 September 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (5) , e477
Abstract
Objective To evaluate the safety and efficacy of cladribine tablets in patients still experiencing active relapsing MS despite interferon (IFN)-β treatment. Methods A 96-week phase II study, randomizing patients treated with IFN-β to cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β. Patients were to receive cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β in a 2:1 ratio (n = 172) with safety and exploratory efficacy outcomes being assessed. Results Adverse events (AEs) and serious AEs were similar across treatment groups, except lymphopenia. Fifty of 124 (40.3%) cladribine/IFN-β recipients vs 0% of placebo/IFN-β recipients reported lymphopenia as an AE, with grade 3/4 lymphopenia (laboratory lymphocyte count < 500 cells/mm3) experienced by 79/124 (63.7%) vs 1 (2.1%), respectively. Patients treated with cladribine tablets 3.5 mg/kg/IFN-β were 63% less likely to have a qualifying relapse than placebo/IFN-β recipients, and cladribine tablets 3.5 mg/kg/IFN-β reduced most MRI measures of disease activity. Conclusions In patients with active relapsing MS despite IFN-β treatment, cladribine tablets 3.5 mg/kg/IFN-β reduced relapses and MRI lesion activity over 96 weeks compared with placebo/IFN-β but led to an increased incidence of lymphopenia. Classification of evidence This study provides Class I evidence that for patients with active relapsing MS despite IFN-β treatment, cladribine tablets added to IFN-β reduced relapses and MRI lesion activity over 96 weeks and increased the incidence of lymphopenia. Clinical trial registration NCT00436826.Keywords
This publication has 21 references indexed in Scilit:
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyMultiple Sclerosis Journal, 2017
- The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Update on Disease-Modifying Treatments for Multiple SclerosisClinical Therapeutics, 2014
- Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trialJournal of Neurology, 2012
- CladribineClinical Neuropharmacology, 2011
- Combination therapy in multiple sclerosisThe Lancet Neurology, 2010
- Results of the Avonex Combination Trial (ACT) in relapsing-remitting MSNeurology, 2009
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple SclerosisDrug Safety, 2004